Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1568 in Healthy Adult Volunteers
Sponsor
Daewoong Pharmaceutical Co. LTD. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT06119945
Collaborator
(none)
44
1
2
22
60.9
Study Details
Study Description
Brief Summary
This study aims to compare the pharmacokinetics and safety following administration of DWJ1568 and DWC202215 in healthy volunteers
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Detailed Description
The study design is a Randomized, Open-label, Oral, Single-dose, Four-way crossover study. The patients were randomly assigned to each group. Primary endpoint was Cmax and AUCt of DWJ1568 and DWC202215. Secondary endpoints were AUCinf, Tmax, t1/2 of DWJ1568 and DWC202215.
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
44 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
An Open-label, Randomized, 2x4 Crossover Study to Compare the Pharmacokinetics and Safety Following Administration of DWJ1568 and DWC202215 in Healthy Volunteers
Anticipated Study Start Date
:
Nov 9, 2023
Anticipated Primary Completion Date
:
Dec 1, 2023
Anticipated Study Completion Date
:
Dec 1, 2023
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: DWJ1568 DWJ1568 |
Drug: DWJ1568
One tablet of DWJ1568
|
Active Comparator: DWC202215 DWC202215 |
Drug: DWC202215
One tablet of DWC202215
|
Outcome Measures
Primary Outcome Measures
- Cmax,ss of DWJ1568 and DWC202215 [At pre-dose (0 hour), and post-dose 0 to 72 hour.]
- AUCt of DWJ1568 and DWC202215 [At pre-dose (0 hour), and post-dose 0 to 72 hour.]
Secondary Outcome Measures
- AUCinf of DWJ1568 and DWC202215 [At pre-dose (0 hour), and post-dose 0 to 72 hour.]
- Tmax of DWJ1568 and DWC202215 [At pre-dose (0 hour), and post-dose 0 to 72 hour.]
- AUCt/AUCinf of DWJ1568 and DWC202215 [At pre-dose (0 hour), and post-dose 0 to 72 hour.]
- t1/2 of DWJ1568 and DWC202215 [At pre-dose (0 hour), and post-dose 0 to 72 hour.]
Eligibility Criteria
Criteria
Ages Eligible for Study:
19 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
- over 19 year old
Exclusion Criteria:
-
Galactose intolerance
-
Lapp lactase deficiency
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | H Plus YANGJI Hospital | Seoul | Korea, Republic of |
Sponsors and Collaborators
- Daewoong Pharmaceutical Co. LTD.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Daewoong Pharmaceutical Co. LTD.
ClinicalTrials.gov Identifier:
NCT06119945
Other Study ID Numbers:
- DWJ1568101
First Posted:
Nov 7, 2023
Last Update Posted:
Nov 7, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No